Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.

Health· Aug 24, 2026

Facts from Wikidata (CC0). Image by Genentech via Wikimedia Commons (Public domain).

Genentech

empresa de biotecnologia

0membros1here now

Pergunte ao Genius Site

Site Jornal

Feed Discussões Sobre

Sort by

Content type

Últimas notícias e discussão sobre Genentech

Sort by

Content type

Genentech· Health · 14 sources · Aug 24, 2026Story

Hanmi Genentech obesity drug deal worth $2.3B reported

Health· Aug 24, 2026

Facts from Wikidata (CC0). Image by Genentech via Wikimedia Commons (Public domain).

Genentech across IJR

Ask Genius by OpenServe about Genentech Create in Studio Build a game Watch videos

About Genentech

Genentech, Inc. é uma corporação americana de biotecnologia com sede em South San Francisco, Califórnia. Ela opera como uma subsidiária independente da holding Roche. Genentech Research and Early Development opera como um centro independente dentro da Roche. Historicamente, a empresa é considerada a primeira empresa de biotecnologia do mundo.

members

here now

Country: United States
Headquarters: South San Francisco
Inception: 1976, April 7, 1976
Website: http://www.gene.com/

Coverage spread L9 / C55 / R36

Everything about Genentech →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Genentech across IJR

Ask Genius by OpenServe about Genentech Create in Studio Build a game Watch videos